meta|evidence oncology
  • Living systematic review and meta-analysis
  • AKT inhibitor
  • capivasertib based treatment
  • capivasertib plus paclitaxel
  • ipatasertib based treatment
  • ipatasertib plus paclitaxel
  • antibody–drug conjugate
  • sacituzumab govitecan
  • trastuzumab deruxtecan
  • trastuzumab emtansine
  • trastuzumab emtasine plus endocrine therapy
  • aurora kinase inhibitors
  • alisertib plus paclitaxel
  • biguanide
  • metformin
  • celecoxib plus endocrine therapy
  • chemotherapy
  • non platinum-based chemotherapy
  • nucleoside analogues (pyrimidine/purine)
  • capecitabine
  • Standard of Care (SoC)
  • cyclin inhibitor
  • abemaciclib based treatment
  • abemaciclib plus aromatase inhibitor
  • abemaciclib plus endocrine therapy
  • abemaciclib plus fulvestrant
  • dalpiciclib plus fulvestrant
  • palbociclib based treatment
  • palbociclib
  • palbociclib plus endocrine therapy
  • palbociclib plus fulvestrant
  • palbociclib plus letrozole
  • ribociclib based treatment
  • ribociclib plus endocrine therapy
  • ribociclib plus fulvestrant
  • ribociclib plus letrozole
  • endocrine therapy
  • androgen deprivation therapy (ADT)
  • abiraterone plus ADT
  • abiraterone plus docetaxel plus ADT
  • apalutamide plus ADT
  • darolutamide plus doxetaxel plus ADT
  • docetaxel plus ADT
  • enzalutamide
  • enzalutamide plus ADT
  • gene alteration target therapy
  • BRAF gene alteration targeted therapy
  • BRAF inhibitor
  • combined BRAF-MEK inhibitors
  • trametinib plus dabrafenib
  • KRAS gene alteration targeted therapy
  • sotorasib
  • MET gene alteration targeted therapy
  • capmatinib
  • NTRK gene alteration targeted therapy
  • entrectinib
  • larotrectinib
  • RET gene alteration targeted therapy
  • pralsetinib
  • selpercatinib
  • HDAC inhibitor
  • entinostat plus exemestane
  • tucidinostat based treatment
  • tucidinostat plus exemestane
  • HER inhibitor
  • EGFR inhibitor
  • afatinib based treatment
  • afatinib plus vinorelbine
  • HER2 inhibitor
  • neratinib based treatment
  • neratinib
  • neratinib plus capecitabine
  • pertuzumab based treatment
  • pertuzumab plus trastuzumab
  • pertuzumab plus trastuzumab plus docetaxel
  • trastuzumab based treatment
  • docetaxel plus carboplatin with trastuzumab followed by trastuzumab
  • doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab
  • trastuzumab plus endocrine therapy
  • trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel
  • tucatinib based treatment
  • tucatinib plus trastuzumab plus capecitabine
  • TKI anti HER1/EGFR and HER2/neu
  • lapatinib based treatment
  • lapatinib
  • lapatinib plus capecitabine
  • lapatinib plus fulvestrant
  • lapatinib plus letrozole
  • lapatinib plus paclitaxel
  • lapatinib plus trastuzumab
  • lapatinib plus trastuzumab plus paclitaxel
  • IGF-1R inhibitors
  • dalotuzumab plus ridaforolimus plus exemestane
  • ganitumab plus endocrine therapy
  • immune chekpoint inhibitors
  • anti-CTLA-4
  • ipilimumab based treatment
  • ipilimumab alone
  • Ipilimumab (10 mg/kg)
  • ipilimumab plus gp100
  • ipilimumab plus SoC
  • tremelimumab
  • anti-PD-(L)1
  • atezolizumab based treatment
  • atezolizumab alone
  • atezolizumab plus bevacizumab
  • atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
  • atezolizumab plus cabozantinib
  • atezolizumab plus carboplatin plus nab-paclitaxel
  • atezolizumab plus carboplatin plus paclitaxel
  • atezolizumab plus cometinib
  • atezolizumab plus FOLFOXIRI plus bevacizumab
  • atezolizumab plus nab-paclitaxel
  • atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide
  • atezolizumab plus paclitaxel
  • atezolizumab plus pemetrexed and platin
  • atezolizumab plus SoC
  • avelumab based treatment
  • avelumab alone
  • avelumab plus axitinib
  • avelumab plus pegylated liposomal doxorubicin
  • avelumab plus SoC
  • camrelizumab based treatment
  • camrelizumab alone
  • cemiplimab
  • dostarlimab based treatment
  • dostarlimab plus soC
  • durvalumab based treatment
  • durvalumab alone
  • durvalumab plus bevacizumab
  • durvalumab plus etoposide and platin
  • durvalumab plus olaparib plus SoC
  • durvalumab plus osimertinib
  • durvalumab plus SoC
  • nivolumab based treatment
  • nivolumab alone
  • nivolumab plus cabozantinib
  • nivolumab plus SoC
  • nivolumab followed by ipilimumab
  • pembrolizumab based treatment
  • pembrolizumab alone
  • pembrolizumab (10mg/kg)
  • pembrolizumab (10mg/kg) 2 weeks
  • pembrolizumab (2mg/kg)
  • pembrolizumab and pemetrexed plus platin
  • pembrolizumab plus 5FU plus platin
  • pembrolizumab plus axitinib
  • pembrolizumab plus lenalidomide and dexamethasone
  • pembrolizumab plus lenvatinib
  • pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide
  • pembrolizumab plus pomalidomide and dexamethasone
  • pembrolizumab plus SoC
  • sintilimab based treatment
  • sintilimab
  • sintillimab plus SoC
  • Tislelizumab
  • Immune checkpoint association
  • durvalumab plus tremelimumab
  • durvalumab plus tremelimumab plus SoC
  • nivolumab plus ipilimumab
  • nivolumab plus ipilimumab plus SoC
  • pembrolizumab plus ipilimumab
  • relatlimab plus nivolumab
  • Immunostimulant
  • vaccine
  • AE37 vaccine plus GM-CSF
  • GP2 vaccine plus GM-CSF
  • OBI-822/OBI-821 plus cyclophosphamide
  • inetetamab plus vinorelbine
  • mTOR inhibitors
  • everolimus
  • lenvatinib plus everolimus
  • sapanisertib plus fulvestrant
  • phosphoinositide 3-kinase (PI3K) inhibitor
  • alpelisib based treatment
  • alpelisib plus fulvestrant
  • alpelisib plus letrozole
  • buparlisib based treatment
  • buparlisib plus fulvestrant
  • buparlisib plus letrozole
  • taselisib based treatment
  • taselisib plus letrozole
  • poly ADP-ribose polymerase (PARP) inhibitor
  • niraparib
  • olaparib
  • rucaparib
  • talazoparib
  • veliparib plus paclitaxel plus carboplatin
  • target therapy
  • margetuximab based treatment
  • margetuximab plus chemotherapy
  • multikinase inhibitor
  • nintedanib
  • VEGF(R) inhibitor
  • bevacizumab based treatment
  • bevacizumab
  • bevacizumab plus trastuzumab plus docetaxel
  • cediranib plus fulvestrant
  • lenvatinib
  • lenvatinib in association
  
  • All
  • A EFFACER all cancer
  • basal cell carcinoma
  • biliary tract cancer (BTC)
  • billiary tract cancer - (neo)adjuvant (NA)
  • billiary tract cancer - 1st line (L1)
  • billiary tract cancer - 2nd line (L2)
  • cholangiocarcinoma
  • breast cancer (BC)
  • breast cancer - adjuvant
  • breast cancer - HER2-positive
  • es-BC - HER2 negative - (neo)adjuvant (NA)
  • es-BC - HER2 positive - (neo)adjuvant (NA)
  • la/mBC - HER2 positive
  • la/mBC - HER2 positive - (neo)adjuvant (NA)
  • la/mBC - HER2 positive - 1st Line (L1)
  • la/mBC - HER2 positive - 2nd Line (L2)
  • breast cancer - HR positive
  • es-BC - HR positive - (neo)adjuvant (NA)
  • es-BC - HR-positive - 1st line (L1)
  • la/mBC - HR positive
  • la/mBC - HR positive - (neo)adjuvant (NA)
  • la/mBC - HR positive - NA - PIK3CA mutant
  • la/mBC - HR-positive - 1st line (L1)
  • la/mBC - HR positive - L1 - PIK3CA mutant
  • la/mBC - HR-positive - 2nd line (L2)
  • la/mBC - HR positive - L2 - all population
  • la/mBC - HR positive - L2 - PIK3CA mutant
  • breast cancer - triple negative
  • es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)
  • es-BC - TNBC - NA - all population
  • es-BC - TNBC - NA - PDL1 positive
  • es-BC - Triple negatif (TNBC) - 1st line (L1)
  • mBC - Triple negative (TNBC) - (neo)adjuvant (NA)
  • mBC - Triple negative (TNBC) - 1st Line (L1)
  • mBC - TNBC - L1 - all population
  • mBC - TNBC - L1 - PDL1 positive
  • mBC-Triple negative (TNBC) - 2nd Line (L2)
  • mBC - TNBC - L2 - all population
  • mBC - TNBC - L2 - PDL1 positive
  • metastatic/advanced - breast cancer (mBC)
  • cervical cancer (CC)
  • classical Hodgkin lymphoma (cHL)
  • refractory classic Hodgkin lymphoma (R/R cHL)
  • R/R cHL - second line or more (L2)
  • colorectal cancer (CRC)
  • locally advanced rectal cancer (LARC)
  • metastatic/advanced - colorectal cancer (mCRC)
  • mCRC - (neo)adjuvant (NA)
  • mCRC - 1st line (L1)
  • mCRC - 2nd line (L2)
  • endometrial cancer
  • endometrial cancer - (neo)adjuvant (NA)
  • esophageal cancer (EC)
  • locally advanced - esophageal cancer (laEC)
  • laEC - Neo(adjuvant) (NA)
  • metastatic/advanced - esophageal cancer (mEC)
  • mEC - (neo)adjuvant (NA)
  • mEC - 1st line (L1)
  • mEC - 2nd line (L2)
  • gastric or gastroesophageal junction cancer (GC)
  • locally advanced (laGC)
  • laGC - (neo)adjuvant (NA)
  • metastatic/advanced mGC or mGEJC
  • mGC or mGEJC - 1st line (L1)
  • mGC or mGEJC - L1 - all population
  • mGC or mGEJC - L1 - HER2 neg/PDL1 positive
  • mGC or mGEJC - L1 - HER2 negative
  • mGC or mGEJC - L1 - HER2 positive
  • mGC or mGEJC - L1 - PDL1 positive
  • mGC or mGEJC - 2nd Line (L2)
  • mGC or mGEJC - L2 - all population
  • mGC or mGEJC - L2 - PDL1 positive
  • mGC or mGEJC - maintenance (M)
  • mGC or mGEJC - M - HER2 negative
  • mGC or mGEJC - M - HER2 neg/PDL1 positive
  • gene alteration defined cancer
  • BRAF gene alteration defined cancer
  • BRCA1/2 gene alteration defined cancer
  • EGFR gene alteration defined cancer
  • EGFR exon 20 insertion mutation
  • FGFR (2/3) gene alteration defined cancer
  • KRAS gene alteration defined cancer
  • MET gene alteration defined cancer
  • NTRK gene alteration
  • RET gene alteration defined cancer
  • glioblastoma (GB)
  • metastatic glioblastoma (mGB) - 1st line (L1)
  • metastatic glioblastoma (mGB) - 2nd line (L2)
  • head and neck cancer squamous cell cancer (HNSCC)
  • locally advanced (laHNSCC)
  • laHNSCC - (neo)adjuvant (NA)
  • laHNSCC - 1st line (L1)
  • laHNSCC - 2nd line (L2)
  • metastatic-recurrent HNSCC (mHNSCC)
  • mHNSCC - (neo)adjuvant (NA)
  • mHNSCC - 1st line (L1)
  • mHNSCC - L1 - all population
  • mHNSCC - L1 - PDL1 positive
  • mHNSCC - 2nd line (L2)
  • mHNSCC - L2 - all population
  • mHNSCC - L2 - PDL1 negative
  • mHNSCC - L2 - PDL1 positive
  • hepatocell cancer (HCC)
  • early HCC - (neo)adjuvant (NA)
  • metastatic/advanced hepatocellular cancer (mHCC)
  • mHCC - (neo)adjuvant (NA)
  • mHCC - 1st line (L1)
  • mHCC - 2nd line (L2)
  • lung cancer : non small cell (NSCLC)
  • early NSCLC - (neo)adjuvant (NA)
  • eNSCLC - NA - all population
  • eNSCLC - NA - EGFR mutant
  • early NSCLC - 1st line (L1)
  • locally advanced NSCLC - (neo)adjuvant (NA)
  • laNSCLC - NA - all population
  • locally advanced NSCLC - maintenance (M)
  • laNSCLC - M - all population
  • laNSCLC - M - EGFR mutant
  • metastatic/adv NSCLC (mNSCLC) - (neo)adjuvant (NA)
  • mNSCLC - NA - all population
  • metastatic/adv NSCLC (mNSCLC) - maintenance (M)
  • mNSCLC - M - all population
  • mNSCLC - M - EGFR mutant
  • mNSCLC - M - EGFR wild type
  • mNSCLC - M - PDL1 positive
  • metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
  • mNSCLC - L1 - all population
  • mNSCLC - L1 - EGFR mutant
  • mNSCLC - L1 - PDL1 negative
  • mNSCLC - L1 - PDL1 positive
  • mNSCLC - L1 - TMB>10Mb
  • non squamous cell - mNSCLC - L1
  • non squamous - mNSCLC - L1 - all population
  • non squamous - mNSCLC - L1 - PDL1 positive
  • non squamous - mNSCLC - L1 - Wild Type (WT)
  • squamous cell - mNSCLC - L1
  • squamous - mNSCLC - L1 - all population
  • squamous - mNSCLC - L1 - PDL1 positive
  • squamous - mNSCLC - L1 - Wild Type (WT)
  • metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
  • mNSCLC - L2 - adenocarcinoma cell
  • mNSCLC - L2 - all population
  • mNSCLC - L2 - EGFR high
  • mNSCLC - L2 - EGFR mutant
  • mNSCLC - L2 - EGFR wild type
  • mNSCLC - L2 - KRAS mutant
  • mNSCLC - L2 - KRAS wild type
  • mNSCLC - L2 - PDL1 negative
  • mNSCLC - L2 - PDL1 positive
  • non squamous cell - mNSCLC - L2
  • non squamous - mNSCLC - L2 - all population
  • non squamous - mNSCLC - L2 - EGFR mutant
  • non squamous - mNSCLC - L2 - PDL1 positive
  • non squamous - mNSCLC - L2 - wild type (WT)
  • squamous cell - mNSCLC - L2
  • squamous - mNSCLC - L2 - all population
  • squamous - mNSCLC - L2 - PDL1 positive
  • NSCLC adjuvant setting
  • NSCLC neoadjuvant setting
  • lung cancer : small cell (SCLC)
  • Extensive stage SCLC (Es-SCLC)
  • Extensive stage SCLC (Es-SCLC) - maintenance (M)
  • Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
  • Extensive stage SCLC (Es-SCLC) - 2nd line (L2)
  • limited stage SCLC (ls-SCLC)
  • limited stage SCLC (ls-SCLC) - maintenance (M)
  • limited stage SCLC (ls-SCLC) - 2nd Line (L2)
  • melanoma (ML)
  • metastatic/adv melanoma (mML)
  • mML - (neo)adjuvant (NA)
  • mML - NA - all population
  • mML - NA - PDL1 positive
  • mML - 1st line (L1)
  • mML - L1 - all population
  • mML - L1 - BRAF mutant
  • mML - L1 - BRAF wild
  • mML - 2nd line (L2)
  • mML - L2 - all population
  • mML - L2 - BRAF mutant
  • mesothelioma (MS)
  • malignant mesothelioma (mMS) - (neo)adjuvant (NA)
  • malignant mesothelioma (mMS) - 1st line (L1)
  • malignant mesothelioma (mMS) - 2nd line (L2)
  • multiple myeloma
  • multiple myeloma - 1st line (L1)
  • multiple myeloma - 2nd line (L2)
  • myofibroblastic tumors
  • neurofibroma
  • neutropenia
  • new pathology
  • osteosarcoma
  • ovarian cancer (OC)
  • metastatic/advanced OC (mOC) - (neo)adjuvant (NA)
  • metastatic/advanced OC (mOC) - 1st line (L1)
  • mOC - L1 - all population
  • mOC - L1 - PDL1 positive
  • metastatic/advanced OC (mOC) - 2nd line (L2)
  • metastatic/advanced OC (mOC) - maintenance (M)
  • pancreatic ductal adenocarcinoma
  • PIK3CA-related overgrowth spectrum
  • prostate cancer (PC)
  • castration-resistant prostate cancer (CRPC)
  • metastatic (mCRPC) - 1st line (L1)
  • metastatic (mCRPC) - 2nd line (L2)
  • metastatic, hormone-sensitive prostate cancer
  • renal cell cancer (RCC)
  • metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)
  • metastatic/advanced RCC (mRCC) - 1st line (L1)
  • mRCC - L1 - PDL1 negative
  • mRCC - L1 - PDL1 positive
  • metastatic/advanced RCC (mRCC) - 2nd line (L2)
  • sarcomas
  • thyroid cancer
  • urothelial cancer (UC) - bladder cancer (BC)
  • metastatic/advanced UC (mUC) - 1st Line (L1)
  • mUC - L1 - all population
  • mUC - L1 - PDL1 positive
  • metastatic/advanced UC (mUC) - 2nd Line (L2)
  • mUC - L2 - all population
  • mUC - L2 - PDL1 positive
  • metastatic/advanced UC (mUC) - maintenance (M)
  • mUC - M - all population
  • mUC - M - PDL1 positive
  • muscular invasive bladder cancer (MIBC)
  • MIBC - (neo)adjuvant (NA)
  • MIBC - NA - all population
  • MIBC - NA - PDL1 positive
  • non-muscle-invasive BC (NMIBC)
  • NMIBC - (neo)adjuvant (NA)
  • NMIBC - 1st line (L1)
  • NMIBC - 2nd line (L2)